Acta Ortopédica Mexicana

García-Reyna JC, Rico MG, Vega GIF, Linares LM, Delgado CEA, Romero RR
Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin
Acta Ortop Mex 2008; 22 (6)

Language: Español
References: 23
Page: 390-396
PDF: 230.08 Kb.

[Fulltext - PDF]

ABSTRACT

Introduction: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker. Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%. It is used as a predictor of therapy efficacy and to localize remaining and recurrent tissue as well as local and distant extension. Objective: To determine the sensitivity, specificity and predictive values of the three-phase 99mTc-Tetrofosmin scan in detection of malignant lesions of the musculoskeletal tissue. Methods: Seventy-three patients of both genders with suspected malignant musculoskeletal lesions were studied by three-phase (vascular, tissue and delayed images) 99mTc-tectrofosmin scans. Results: One-hundred-percent sensitivity, 67.3% specificity, 55% positive predictive value, and 100% negative predictive value. Conclusion: Three-phase 99mTc-tectrofosmin scan is useful in detection of malignant lesions of the musculoskeletal system due to its high sensitivity and positive predictive value. Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.


Key words: bone tumors, (99m)-Tetrofosmin scan, screening tests.


REFERENCES

  1. Engels AE, Fraumeni FJ, Jr: New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. New malignancies following cancer of the bone and soft tissue and Kaposi sarcoma. National Cancer Institute. NIH Publ. Bethesda, MD, 2006; (05)5302: 313-23.

  2. Jemal A, Murray T, Ward E, et al: Cancer statistics CA. Cancer J Clin 2005; 55: 10-30.

  3. Fukumoto M: Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI and 99mTc-tetrofosmin. Ann Nucl Med 2004; 18(2): 79-95.

  4. Fuster D, Vinolas N, Mallafre C, Pavia J, Martin F, Pons F: Tetrofosmin as predictors of tumor response. Q J Nucl Med 2003; 471(1): 58-62.

  5. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A: Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34(1): 30-8.

  6. Fattori B, Gross M, Nacci A, Bianchi F, Cosottini M, Ursino F, Manca G, Rubello D, Strauss HW, Mariana G: The role of 99m Tc-tetrofosmin scintigraphy for staging patients with laryngeal cancer. Cancer Biother Radiopharm 2005; 20(1): 27-35.

  7. Smith JR, Oates ME: Radionuclide imaging of the parathyroid glands: patterns, pearls and pitfalls. Radiographics 2004; 24(4): 1101-15.

  8. Karanikas G, Köstler WJ, Becherer A, Wiesner K, Dudczak R, Krainer M, Kletter K: Technetium 99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma. Oncology Reports 2002; 9: 1009-13.

  9. Soderlund V, Jonsson C, Bauer HC, Brosjo O, Jacobsson H: Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 1997; 38(5): 682-6.

  10. Bongers V, Perre C, de Hooge P: The use of scintimammography for detecting the recurrence of loco-regional breast cancer: histopathologically proven results. Nucl Med Commun 2004; 25(2): 145-9.

  11. Klain M, Maurea S, Secondo L, Cuocolo A, Salvatore M: Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 1995; 36(12): 2248-51.

  12. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I: Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38(3): 348-52.

  13. Hashimoto T, Takahashi K, Goto M, Endo H, Kono T, Nishiyama H, et al: Detection of malignant thymoma in primary tumor and metastatic lesions using 99mTc-tetrofosmin scintigraphy. Radiation Medicine 2001; 19(3): 169-72.

  14. Schillaci O, Spanu A, Madeddu G: [99mTc]sestamibi and [99mTc]tetrosfosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging 2005; 49:133-44.

  15. SpanuAlexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S: Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med 2007; 21(5): 293-8. Epub 2007 Jul 25.

  16. Schillaci OA, Madeddu G: 99mTc labeled cationic lipophilic complexes in malignant and benign tumors: the role of SPET and pinhole-SPET in breast cancer, differentiated thyroid carcinoma and hyperparathyroidism. Q J Nucl Med Mol Imaging 2005; 49: 145-69.

  17. Spanu A, Solinas ME, Farris A, Arru A, Chessa F, Madeddu G, Falchi A: The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors. Radiol Med (Torino) 2004; 107(1-2): 113-27.

  18. Wakasugi S, Tsukuma H, Inaji H, Hashizume T, Noguchi A, Ohnishi T: Predictive value of bone marrow accumulation of Tc-99m tetrofosmin for subsequent development of distant metastases in breast cancer. Ann Nucl Med 2007; 21(8): 429-37.

  19. Schillaci O, Spanu A, Scopinaro F, Monteleone F, Masala S, Tarantino U, Madeddu G, Simonetti G: Technetium-99m tetrofosmin scintigraphy in pediatric osteogenic sarcoma. Oncol Rep 2003; 10(3): 605-8.

  20. Meghdadi S, Karanikas G, Schlagbauer-Wadi H, Jansen B, Chehne F, Rodriguez M, Pehamberger H, Sinzinger H: Technetium-99m-Tetrofosmin a new agent for melanoma imaging? Anticancer Res 1998; 18: 2759-62.

  21. Yapar Z, Kibar M, Ozbarlas S, Sahin B, Uguz A, Gonlusen G, Inal ME: Tc-99m-tetrofosmin scintigraphy in a primary giant cell tumor of bone with pulmonary metastases. Ann Nucl Med 2003; 17(2): 153-7.

  22. Yapar Z, Kibar M, Yapar AF, Uguz A, Ozbarlas S, Gonlusen G: The value of Tc-99m-tetrofosmin scintigraphy in the assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors. Ann Nucl Med 2003; 17(6): 443-9.

  23. Yapar Z, Kibar M, Ozbarlas S, Yapar AF, Uguz A, Zorludemir S, Herdem M: 99mTc-tetrofosmin scintigraphy in musculoskeletal tumours: the relationship between P-glycoprotein expression and tetrofosmin uptake in malignant lesions. Nucl Med Commun 2002; 23(10): 991-1000.